Steno Diabetes Center Copenhagen
Gentofte Municipality, 2820, Denmark
NCT Number: NCT04098549
In the effort of better understanding the glucose control in people with type 1 diabetes, in-depth insight into the physiology of hepatic glucose production and its influencing factors is essential. Previously, a number of potential influencing factors of hepatic glucose production have been investigated, including insulin-on-board, low carbohydrate diet, preceding ethanol intake, exercise and multiple stimulations of hepatic glucose production. Previous post-hoc analysis of dual-hormone closed-loop systems has indicated that the rate of fall in blood glucose influences the following stimulation of hepatic glucose response. However, the rate of fall in blood glucose is highly related to insulin levels, which may explain those findings. Thus, in this study the investigators want to examine whether the different rates of fall in blood glucose with similar insulin levels on board affect the hepatic glucose response in individuals with type 1 diabetes. In the study, which will be conducted at Steno Diabetes Center Copenhagen, participants will complete two study visits. On each visit, a hypoglycemic clamp technique will be used to lower the blood glucose levels of the participants (using either a rapid or slow decline rate), whereupon hepatic glucose production will be stimulated using low-dose glucagon. The study days are divided into four phases: 1) preparation phase, 2) hyperinsulinemic euglycemic phase (stabilization of blood glucose), 3) hyperinsulinemic hypoglycemic phase (rapid or slow decline in blood glucose) and 4) post-glucagon administration phase. This design will allow the investigators to examine whether differences in hepatic glucose response exist depending on preceding rate of fall in blood glucose. We hypothesize that the rate of fall in blood glucose does not affect the hepatic glucose production.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Gentofte Municipality, 2820, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Rapid lowering of plasma glucose using hypoglycemic clamp technique
Slow lowering of plasma glucose using hypoglycemic clamp technique
Time frame: from 0-120 minutes after glucagon administration
Time frame: from 0-120 minutes after glucagon administration
Time frame: from 0-120 minutes after glucagon administration
Time frame: from 0-120 minutes after glucagon administration
Time frame: from 0-120 minutes after glucagon administration
Time frame: 120 minutes after glucagon administration
Time frame: from 0-120 minutes after glucagon administration
Time frame: from 0-120 minutes after glucagon administration
Time frame: throughout phase 4 (until 120 minutes after glucagon administration)
Time frame: throughout phase 4 (until 120 minutes after glucagon administration)
Time frame: from 0-120 minutes after glucagon administration
Time frame: from 0-120 minutes after glucagon administration
Time frame: from 0-120 minutes after glucagon administration
Time frame: 0-120 minutes after glucagon administration
Time frame: from baseline to 120 minutes after glucagon administration
Time frame: 0-120 minutes after glucagon administration
Time frame: 0-120 minutes after glucagon administration
Time frame: measured at baseline, 5 minutes prior to the end of phase 2, 5 minutes prior to the end of phase 3 and 30 and 115 minutes after glucagon administration
Time frame: measured at baseline, 5 minutes prior to the end of phase 2, 5 minutes prior to the end of phase 3 and 30 and 115 minutes after glucagon administration
Time frame: from 0-120 minutes after glucagon administration
Steno Diabetes Center Copenhagen
Other
Acronym: RaSlo-19
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06575426
Autoimmune Diseases, Diabetes Mellitus
Chicago, Illinois, United States
View Trial DetailsNCT01897688
Autoimmune Diseases, Diabetes Mellitus
Chicago, Illinois, United States
View Trial DetailsNCT05671679
Autoimmune Diseases, Diabetes Mellitus
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT07373236
Autoimmune Diseases, Diabetes Mellitus
Hellerup, Denmark
View Trial Details